- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03674294
Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy (CINV)
Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed by pathology as gastrointestinal carcinoma and no previous FOLFOX or FOLFIRI based regimen chemotherapy history.
- Female.
- Adult patients ( ≥ 18, ≤ 50 years of age)
- No long-term or excessive alcohol intake history:1.Alcohol intake less than 5 times per week; 2.Alcohol intake less than 100g per day.
- Performance status ECOG 0-1
- Adequate haematological, hepatic, renal and metabolic function parameters:
Leukocytes : 3,500-10,000/mm3, ANC ≥ 1,500/mm3, Platelets ≥ 90,000/mm3, Hb > 9g/dl (may be transfused or treated with erythropoietin to maintain or exceed this level), Serum creatinine ≤ 1 x upper limit of normal, Bilirubin ≤ 1.5 x upper limit of normal, Serum AST, ALT, ALP ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases.
- Negative pregnancy test. If pregnancy test were positive, subject should be included in the trial only when the subsequent pregnancy test is negative.
- Ability of reading, comprehending and finishing trial questionnaires and record, including VAS (Visual Analogue Scale) question.
- Before subject registration, written informed consent must be given according to local regulations.
Exclusion Criteria:
- Pregnant women without morning sickness.
- Presence of gastrointestinal tract obstruction or electrolyte imbalance.
- Any history of central nervous system disease(e.g. Primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke).
- Contraindication of glucocorticoid:1.Infection of virus, bacteria or fungus uncontrolled by antibiotics; 2.Active stomach or duodenum ulcer; 3.Severe hypertension, atherosclerosis, diabetes; 4.Osteoporosis;5.Corneal ulcer; 6.Pregnancy; 7.Reparative phase of trauma, operation or fraction; 8.Hypercortisolism; 9.Severe mental disorder or epilepsy; 10.Inadequate cardiac or renal function.
- Mental disability or severe emotional or mental disorder.
- Active infection(e.g. pneumonia, hepatitis) or any uncontrolled disease(e.g.diabetic ketoacidosis) that may affect study outcome or expose patients to unnecessary risk.
- Usage of any illicit drug, including medical marijuana or alcohol abusing(China drug dependence criteria).
- Treatment of unapproved medicine in the previous 4 weeks.
- Concomitant therapy of psychotropic medicine such as olanzapine.
- Hypersensitivity history towards Aprepitant, 5-HT3 receptor antagonist or dexamethasone.
- Previous treatment of Aprepitant.
- Unable to swallow capsules.
- Main researchers considered that the patient is unsuited to the trial.
- Unable or unwilling to follow research programme.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Palonosetron/Dexamethasone/Aprepitant
|
Aprepitant is manufactured by Merck & Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.
It was approved by the FDA in 2003
Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
Dexamethasone is a type of corticosteroid medication.
It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
|
PLACEBO_COMPARATOR: Palonosetron/Dexamethasone/Placebo
|
Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV).
It is used for the control of delayed CINV-nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
Dexamethasone is a type of corticosteroid medication.
It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response rate during the overall phase
Time Frame: Up to 1-2 months
|
The proportion of patients without emesis episodes or rescue medication use during the overall phase (0-120 h)
|
Up to 1-2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response rate in the acute phase
Time Frame: Up to 1-2 months
|
The proportion of patients without emesis episodes or rescue medication use during the acute phase (0-24h)
|
Up to 1-2 months
|
Complete response rate in the delayed phase
Time Frame: Up to 1-2 months
|
The proportion of patients without emesis episodes or rescue medication use during the delayed phase (25-120 h)
|
Up to 1-2 months
|
No vomiting rate in the acute phase, delayed phase and overall phase
Time Frame: Up to 1-2 months
|
The proportion of no vomiting (no vomiting or retching episodes) in the acute phase, delayed phase and overall phase
|
Up to 1-2 months
|
Affection caused by CINV reported by patients
Time Frame: Up to 1-2 months
|
Up to 1-2 months
|
|
Effects of CINV on daily life
Time Frame: Up to 1-2 months
|
Up to 1-2 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Signs and Symptoms, Digestive
- Gastrointestinal Diseases
- Nausea
- Vomiting
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Serotonin Agents
- Serotonin Antagonists
- Serotonin 5-HT3 Receptor Antagonists
- Neurokinin-1 Receptor Antagonists
- Dexamethasone
- Palonosetron
- Aprepitant
Other Study ID Numbers
- Aprepitant-CINV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Neoplasms
-
Novartis PharmaceuticalsActive, not recruitingNeoplasms, Gastrointestinal TractChina, Canada, Estonia, Italy, Turkey, Argentina, Israel, Netherlands, Poland, Russian Federation, Thailand, Brazil, Chile, Hong Kong, Hungary, India, Mexico, Peru, Taiwan, Ukraine, United States, Korea, Republic of, Puerto Rico
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruiting
-
Sun Yat-sen UniversityUnknownGastrointestinal CancersChina
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompleted
-
Peking University Cancer Hospital & InstituteActive, not recruitingGastrointestinal CancerChina
-
Brigette MaRecruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdJiangsu Alphamab Biopharmaceuticals Co., LtdRecruitingAdvanced Gastrointestinal TumorsChina
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Henan Cancer HospitalUnknownAdvanced Gastrointestinal TumorsChina
Clinical Trials on Aprepitant
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting
-
Merck Sharp & Dohme LLCCompletedChemotherapy Induced Nausea and Vomiting
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
-
The Hospital for Sick ChildrenCompletedChemotherapy-induced Nausea and VomitingCanada
-
University of VirginiaNational Institute on Drug Abuse (NIDA)CompletedCannabis Dependence | Nicotine Dependence | Marijuana Dependence | Cannabis Abuse | Nicotine WithdrawalUnited States
-
University Hospital, RouenCompleted
-
Sharon WalshNational Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLCCompleted
-
Duke UniversityMerck Sharp & Dohme LLCCompleted
-
University of NebraskaWithdrawnPostoperative Nausea and VomitingUnited States